Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tenuifoliside A is a bioactive oligosaccharide ester isolated from the roots of *Polygala tenuifolia*, a traditional Chinese medicinal plant. It exhibits anti-apoptotic, neuroprotective, and antidepressant-like effects. Mechanistically, Tenuifoliside A promotes neuronal survival and neurite outgrowth by activating the ERK/CREB/BDNF signaling pathway and enhancing phosphorylation of ERK (extracellular signal-regulated kinase), Akt (protein kinase B), and CREB (cyclic AMP response element-binding protein). Its anti-inflammatory activity is mediated through inhibition of the NF-κB and MAPK pathways. Preclinical studies suggest potential for use in depressive disorders and neuroprotection[1][2][4][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tenuifoliside a.